Premium
CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30‐POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202)
Author(s) -
Sawas A.,
Chen P.,
Vlad G.,
Lipschitz M.,
AbdulHay M.,
Lue J.,
Deng C.,
Amengual J.E.,
Marchi E.,
Shulman J.,
Elgedawe H.,
Shong M.V.,
Khan K.,
Geskin L.,
Rodig S.J.,
O'Connor O.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.123_2630
Subject(s) - medicine , brentuximab vedotin , cd30 , flow cytometry , gastroenterology , biomarker , lymphoma , refractory (planetary science) , cohort , immunology , biochemistry , chemistry , physics , astrobiology